Regeneron Pharmaceuticals Inc (BSP:REGN34)
R$ 89.25 1.25 (1.42%) Market Cap: 590.31 Bil Enterprise Value: 549.72 Bil PE Ratio: 24.59 PB Ratio: 3.63 GF Score: 86/100

Q4 2018 Regeneron Pharmaceuticals Inc Earnings Call Transcript

Feb 06, 2019 / 01:30PM GMT
Operator

Welcome to the Regeneron Pharmaceuticals Fourth Quarter 2018 Earnings Conference Call. My name is Paulette, and I will be your operator for today's call. (Operator Instructions) Please note that this conference is being recorded.

I will now turn the call over to Mark Hudson, Senior Manager, Investor Relations. You may begin.

Mark Hudson
Regeneron Pharmaceuticals, Inc. - IR Executive

Thank you, Paulette. Good morning, and welcome to Regeneron Pharmaceuticals' Fourth Quarter 2018 Conference Call. An archive of this webcast will be available on our website for 30 days under Events.

Joining me on the call today are Dr. Leonard Schleifer, Founder, President and Chief Executive Officer; Dr. George Yancopoulos, Founding Scientist, President and Chief Scientific Officer; Marion McCourt, Senior Vice President and Head of Commercial; and Bob Landry, Executive Vice President and Chief Financial Officer. After our prepared remarks, we'll open up the call for Q&A.

I would also like to remind you that remarks made on this call today include

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot